Comparative Pharmacology
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus PREVACID NAPRAPAC 375 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus PREVACID NAPRAPAC 375 COPACKAGED.
ASPRUZYO SPRINKLE vs PREVACID NAPRAPAC 375 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASPRUZYO SPRINKLE (lacosamide) enhances slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting repetitive neuronal firing.
Lansoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell. Naproxen, a nonsteroidal anti-inflammatory drug, inhibits cyclooxygenase (COX-1 and COX-2) reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Oral: 30 mg once daily, with or without food. Sprinkle capsules can be opened and contents mixed with soft food or liquid.
One tablet (naproxen 375 mg / lansoprazole 15 mg) orally twice daily.
None Documented
None Documented
Terminal half-life is approximately 20-30 hours, allowing for once-daily dosing. Steady-state achieved within 5-7 days.
Naproxen: 12-17 hours (mean 14 hours); allows twice-daily dosing. Lansoprazole: 1.5-2 hours (fast metabolizers) to 3-4 hours (slow metabolizers); clinically negligible due to irreversibly binding to proton pumps.
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with <2% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of metabolites.
Naproxen: Approximately 95% excreted in urine as unchanged naproxen (10%) and metabolites (~60% 6-O-desmethylnaproxen and conjugates); <5% in feces. Lansoprazole: Primarily metabolized in liver; metabolites excreted in urine (14-23%) and feces (~22%).
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination